Eastwood Bio-Medical Canada Inc
1.92
CAD
+0.23
(+13.61%)
ISIN
CA27783W1059
CUSIP
27783W105
Return %
Stock
S&P 500
1Y
249.09
14.20
3Y
284.00
81.12
5Y
31.51
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Quarterly Revenue
CAD
•
in mil. unless spec.Quarterly Earnings Per Share
CAD
•
in mil. unless spec.Quarterly Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- CEO
- Youngsoo Kim
- Full Time Employees
- 3
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 4871 Shell Road Richmond BC Canada V6X 3Z6
- IPO Date
- Sep 4, 2014
- Website
- eleotincanada.com
- Similar Companies
- Business
- Eastwood Bio-Medical Canada Inc. is a British Columbia-based company specializing in the research, development, marketing, and distribution of natural health products across North America and Asia. The company operates primarily in the natural health product industry with a focus on metabolic health disorders. Its core product line, Eleotin, comprises a range of scientifically formulated natural remedies presented in tea and capsule forms targeting blood glucose disorders, hypertension, obesity, and related metabolic conditions. Eleotin products include Eleotin A 700 for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative use; Eleotin Cal20 and V3D for bone and teeth health; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. Additional products like Eleotin Bentley promote healthy glucose levels, while Eleotin LBM is recommended for hypertension relief. These products have secured Health Canada product license numbers, affirming regulatory compliance. Founded in 2010 and headquartered in Richmond, British Columbia, Eastwood Bio-Medical Canada has been expanding its operational capabilities by acquiring manufacturing assets from Eastwood Bio-Medical Research Inc., allowing for in-house production of powdered natural health products such as meal replacement foods and supplement sachets. This acquisition aims to reduce manufacturing costs and accelerate research and development, facilitating faster market launches of new products. In recent years, the company has strengthened its position as a fully integrated natural health product company. It maintains strategic operations in Canada, the United States, and Asia to serve its diverse consumer base. Recent developments include continued enhancements in its Eleotin product range and a focus on improving financial performance amid a challenging market environment. The company reported a revenue decline for fiscal year 2024 but showed an overall improvement in net loss figures. Share activity has been noted with price surges driven by investor interest. Eastwood Bio-Medical Canada pursues growth through product innovation, manufacturing integration, and expanded market presence in the natural health sector. Overall, Eastwood Bio-Medical Canada Inc. offers a comprehensive portfolio of licensed natural health products aimed at metabolic health management, supported by recent strategic asset acquisitions and ongoing product development to strengthen its market position in North American and Asian markets.